中金：维持爱康医疗(01789)“跑赢行业”评级上调目标价至7.63港元_老虎社区_美港股上老虎

中金：维持爱康医疗(01789)“跑赢行业”评级上调目标价至7.63港元

智通财经03-30

智通财经APP获悉，中金发布研报称，维持爱康医疗(01789)“跑赢行业”评级，现价对应26-27年13.9/11.2x P/E。考虑板块估值回暖，上调目标价7.3%至7.63港元，对应26-27年18.3/14.7x P/E，较最新收盘价有31.3%的上升空间。考虑海外业务高增及机器人商业化进展，该行上调26年EPS预测3.9%至0.37元，引入27年EPS预测0.46元。公司公布25全年业绩，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2623627023?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-30 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623627023","market":"us","top_or_hot":-1,"title":"中金：维持爱康医疗(01789)“跑赢行业”评级 上调目标价至7.63港元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，中金发布研报称，维持爱康医疗(01789)“跑赢行业”评级，现价对应26-27年13.9/11.2x P/E。考虑板块估值回暖，上调目标价7.3%至7.63港元，对应26-27年18.3/14.7x P/E，较最新收盘价有31.3%的上升空间。考虑海外业务高增及机器人商业化进展，该行上调26年EPS预测3.9%至0.37元，引入27年EPS预测0.46元。公司公布25全年业绩，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1421519.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中金：维持爱康医疗(01789)“跑赢行业”评级 上调目标价至7.63港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中金：维持爱康医疗(01789)“跑赢行业”评级 上调目标价至7.63港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-30 10:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1421519.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中金发布研报称，维持爱康医疗(01789)“跑赢行业”评级，现价对应26-27年13.9/11.2x P/E。考虑板块估值回暖，上调目标价7.3%至7.63港元，对应26-27年18.3/14.7x P/E，较最新收盘价有31.3%的上升空间。考虑海外业务高增及机器人商业化进展，该行上调26年EPS预测3.9%至0.37元，引入27年EPS预测0.46元。公司公布25全年业绩，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1421519.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01789","symbol_name":"爱康医疗","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1421519.html","article_id":"2623627023","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623627023","pubTimestamp":1774836841,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，中金发布研报称，维持爱康医疗“跑赢行业”评级，现价对应26-27年13.9/11.2x P/E。考虑板块估值回暖，上调目标价7.3%至7.63港元，对应26-27年18.3/14.7x P/E，较最新收盘价有31.3%的上升空间。考虑海外业务高增及机器人商业化进展，该行上调26年EPS预测3.9%至0.37元，引入27年EPS预测0.46元。公司持续注重股东回报，拟派分红1.19亿元，计划以1.5亿港元回购股份。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"01789":"爱康医疗"},"translate_title":"CICC: Maintain the \"Outperform\" rating of Aikang Medical (01789) and raise the target price to HK$7.63","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01789":1.5},"content_text":"智通财经APP获悉，中金发布研报称，维持爱康医疗(01789)“跑赢行业”评级，现价对应26-27年13.9/11.2x P/E。考虑板块估值回暖，上调目标价7.3%至7.63港元，对应26-27年18.3/14.7x P/E，较最新收盘价有31.3%的上升空间。考虑海外业务高增及机器人商业化进展，该行上调26年EPS预测3.9%至0.37元，引入27年EPS预测0.46元。公司公布25全年业绩，收入14.82亿元，同比+10%;归母净利润3.39亿元，同比+24%，对应每股盈利0.3元，符合该行预期。随关节集采全面落地，国内市场进入带量范围内手术量稳步增长的常态化阶段，带动髋膝关节全年收入12.81亿元(+13.0%)。25年数字骨科及定制化服务收入＋22.8%，骨科机器人收入增长超200%，带动手术4000台。25全年毛利率提升至60.5%，得益于海外出口业务及高毛利的数字骨科占比提升。25年海外收入3.30亿元(+20.1%)，“JRI+AK”双品牌战略成效显著。运营端效率大幅提升，25年存货周转天数减少72天;经营现金流占净利比重120%。公司持续注重股东回报，拟派分红1.19亿元，计划以1.5亿港元回购股份。研发端，磁控无创可延长假体及髋关节假体组件等新品进入创新通道，8项产品获国家创新支持。根据公司业绩会，公司26年将加速装机，目标投放100-120台设备，带动1-1.4万台手术，实现机器人业务收入约4000万元。产品端，K3+全关节机器人已于26年1月获证，公司预计VTS及K3系统将于26-27年获CE认证。该行认为公司有望以“导航/机器人+耗材”闭环模式，实现新兴业务规模化贡献。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}